US Injectable Drug Delivery Market

The US injectable drug delivery market is projected to reach USD 465.15 billion by 2031 from USD 309.90 billion in 2026, growing at a CAGR of 8.5% during the forecast period.

The growth of the global US injectable drug delivery market is driven by rising outsourcing of formulation development, fill-finish, and manufacturing activities as pharmaceutical and biotechnology companies aim to optimize costs, accelerate commercial timelines, and leverage external technical expertise. The increasing incidence of chronic diseases such as cancer, diabetes, autoimmune disorders, and infectious conditions is driving sustained demand for biologics, biosimilars, gene therapies, and long-acting injectables, thereby strengthening the need for advanced delivery systems. The shift toward personalized medicine, controlled-release systems, and self-administration therapies is expanding opportunities for device innovation, including prefilled syringes, auto-injectors, wearable injectors, and smart connected delivery platforms. Adoption of digital health, remote patient monitoring, real-time adherence tracking, and data-driven dosing decisions is further widening the scope of injectable delivery solutions. The integration of advanced technologies, such as artificial intelligence, robotics, process automation, and continuous manufacturing, is improving efficiency, ensuring sterility, and enhancing quality outcomes in production workflows. Increasing regulatory scrutiny, patent expirations, rising investment in biologics manufacturing, expanding home-based care models, and growing strategic collaborations between device companies, biopharma, and CDMOs are further accelerating the strong expansion of the US injectable drug delivery market.

To know about the assumptions considered for the study download the pdf brochure

The prominent US injectable drug delivery device manufacturers are BD (US), West Pharmaceutical Services, Inc. (US), Cardinal Health (US), Baxter (US), B. Braun SE (Germany), among others, whereas US injectable drug delivery formulation manufacturers are Pfizer Inc. (US), Johnson & Johnson (US), Merck & Co., Inc. (US), Eli Lilly and Company (US), AbbVie Inc. (US), among others. These companies have implemented a range of growth strategies, including both organic and inorganic approaches, such as introducing new products, forming strategic partnerships, and expanding into emerging markets. These initiatives are aimed at enhancing their market share and diversifying their portfolios.

In January 2025, BD (US) announced investments in its US manufacturing network to add capacity for critical medical devices, including syringes, needles, and IV catheters, to meet the ongoing needs of the healthcare system.

In August 2024, Johnson & Johnson Services, Inc. (US) announced that the US FDA approved the first and only IL-23 inhibitor, TREMFYA, with both subcutaneous and intravenous induction options for adult Crohn’s disease patients.

US Injectable Drug Delivery Device Manufacturers

BD is a global medical technology leader providing a wide range of medical devices, instruments, systems, and reagents across more than 190 countries. The company operates through three main segments—BD Medical, BD Life Sciences, and BD Interventional. BD Medical encompasses Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring. Its Pharmaceutical Systems unit supplies needles, syringes, and IV catheters, which are widely used in drug delivery. The Life Sciences segment spans Integrated Diagnostic Solutions and Biosciences, while the Interventional segment covers Surgery, Peripheral Intervention, and Urology & Critical Care, focusing on minimally invasive and critical care devices. BD’s global footprint is supported by key subsidiaries in the US, Canada, and Germany, and in 2025 the company was recognized by Fortune as one of America’s most innovative companies, ranking in the top 25% for advancements in health technology.

West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, operating through two segments: Proprietary Products and Contract Manufactured Products. The Proprietary Products segment offers specialized packaging, containment solutions, drug delivery components, and analytical services to biologic, generic, and pharmaceutical customers, while the Contract Manufactured Products segment designs and produces complex medical, diagnostic, and pharmaceutical devices through its fully integrated manufacturing and automation capabilities. The company has a global presence across the US, Germany, France, and other European and Asia-Pacific regions.

US Injectable Drug Delivery Formulation Manufacturers

Pfizer Inc. is a global biopharmaceutical company engaged in developing, manufacturing, and marketing medicines, vaccines, and consumer healthcare products, operating through three key segments: Biopharma, Pfizer CentreOne, and Pfizer Ignite. Pfizer CentreOne serves as the company’s contract manufacturing arm for specialty APIs, while Pfizer Ignite supports biotech partners with R&D services aligned to Pfizer’s scientific priorities. The Biopharma division oversees the company’s core therapeutics and vaccines. As of 2024, it was restructured into the Pfizer Oncology, Pfizer US Commercial, and Pfizer International Commercial divisions, with sterile injectables offered through the International Commercial subsegment. Pfizer maintains a broad global footprint across more than 40 countries, supported by extensive manufacturing operations in major regions and subsidiaries.

Johnson & Johnson is a leading global healthcare company involved in the R&D, manufacturing, and marketing of medical and therapeutic products, operating through two major segments: Innovative Medicine and MedTech. The Innovative Medicine division offers treatments across various specialties, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular conditions, and metabolic disorders. These treatments are distributed through retailers, wholesalers, distributors, and hospitals. Key injectable therapies in this segment include REMICADE for autoimmune diseases, SIMPONI for rheumatoid arthritis, STELARA for plaque psoriasis, TREMFYA for psoriatic arthritis and ulcerative colitis, and DARZALEX, which surpassed USD 3 billion in quarterly sales for multiple myeloma treatment. Johnson & Johnson maintains a strong presence in more than 60 countries, supported by over 265 operating companies and major subsidiaries.

Market Ranking (Device Manufacturers)

The top five US injectable drug delivery device companies are BD (US), West Pharmaceutical Services, Inc. (US), Cardinal Health (US), Baxter (US), and B. Braun SE (Germany). BD is expanding its presence in the injectable drug delivery market through its broad portfolio of pre-fillable syringes, safety-engineered injection devices, and advanced delivery solutions that support the growing pipeline of biologics and vaccines. West Pharmaceutical Services is strengthening its leadership by scaling high-quality elastomer components, containment systems, and integrated drug–device platforms tailored for complex injectable formulations. Cardinal Health continues to enhance its role by leveraging its extensive distribution network, sterile compounding capabilities, and support services for hospital-administered and specialty injectables. Baxter is advancing its injectable solutions offering with ready-to-use sterile injectables and parenteral products designed for critical care and chronic disease management. B. Braun SE is reinforcing its position through a comprehensive range of safety-engineered delivery devices that improve medication administration and patient safety across global healthcare settings.

Market Ranking (Formulation Manufacturers)

The top five US injectable drug delivery formulation companies are Pfizer Inc. (US), Johnson & Johnson (US), Merck & Co., Inc. (US), Eli Lilly and Company (US and AbbVie Inc. (US). Pfizer Inc. is expanding its injectable drug delivery footprint through its broad portfolio of sterile injectables, biologics, and oncology therapies, supported by a global manufacturing network that enhances capacity and supply reliability. Johnson & Johnson is strengthening its position in the injectable therapeutics space with its extensive portfolio of immunology, oncology, and neuroscience injectables, leveraging the capabilities of its Janssen division to drive innovation and scale. Merck & Co., Inc. continues to advance its injectable offerings by building on its strong pipeline in oncology, vaccines, and infectious diseases, supported by robust clinical development and commercial manufacturing capabilities. Eli Lilly and Company is deepening its presence in the injectable market with a rapidly growing portfolio in diabetes, obesity, and immunology, supported by large-scale investments in advanced manufacturing and device innovation. AbbVie Inc. reinforces its leadership through its established portfolio of biologic injectables in immunology and oncology, combining formulation expertise and device integration to deliver high-impact therapeutic solutions.

Related Reports:

US Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com